scispace - formally typeset
E

Eero Vasar

Researcher at University of Tartu

Publications -  274
Citations -  7726

Eero Vasar is an academic researcher from University of Tartu. The author has contributed to research in topics: Receptor & Cholecystokinin. The author has an hindex of 43, co-authored 263 publications receiving 6930 citations. Previous affiliations of Eero Vasar include University of Copenhagen & Tallinn University of Technology.

Papers
More filters
Journal ArticleDOI

Wfs1‐deficient animals have brain‐region‐specific changes of Na+, K+‐ATPase activity and mRNA expression of α1 and β1 subunits

TL;DR: It is shown that Wfs1‐deficient mice have brain‐region‐specific changes in Na+,K+‐ATPase activity and in the expression of the α1 and β1 subunits, which is probably related to the dysfunction of ER stress regulation, which leads to cell apoptosis.
Journal ArticleDOI

Repeated Administration of D-Amphetamine Induces Distinct Alterations in Behavior and Metabolite Levels in 129Sv and Bl6 Mouse Strains.

TL;DR: Pooled data from both strains showed that the elevation of isoleucine and leucine was a prominent biomarker of AMPH-induced behavioral sensitization, and Hexoses and kynurenine were reduced after repeated AMPH compared to saline in 129Sv.
Journal ArticleDOI

Cat odor exposure induces distinct changes in the exploratory behavior and Wfs1 gene expression in C57Bl/6 and 129Sv mice.

TL;DR: Dynamics of Wfs1 gene expression and exploratory behavior suggest that the down-regulation of WFS1 gene in Bl6 mice might be related to the increased anxiety.
Journal ArticleDOI

Intracerebroventricular administration of cholecystokinin inhibits the activity of the dopaminergic and serotoninergic systems of the brain.

TL;DR: It can be assumed that cholecystokinin is an endogenous modulator of the activity of the monoaminergic systems of the brain.
Journal ArticleDOI

Variability in the effect of antidepressants upon Wfs1-deficient mice is dependent on the drugs’ mechanism of actions

TL;DR: The results of this study suggest that SSRIs are the drugs of choice for the treatment of depressive symptoms in diabetic patients and employing the mechanism of action of ketamine that affected glucose metabolism positively, could be an approach for development of improved antidepressants.